Allergy Therapeutics Advances Peanut Allergy Vaccine Candidate to Final Phase of Clinical Trial
Why we think this is neutral
This RNS announcement provides a general update on the progress of Allergy Therapeutics' VLP Peanut vaccine candidate, including the advancement of the Phase I/IIa PROTECT trial to the final phase of treatment. While the update indicates positive progress, it does not contain any of the mandatory news types specified, such as contract news, order news, or financial results. Therefore, a neutral sentiment score is appropriate.
Key Points
- Healthy volunteers now receiving highest doses with no safety signals observed
- Third cohort of peanut allergic patients progressing through therapeutic dose range
- New peer-reviewed publication validates mechanism of action of VLP Peanut vaccine
Summary
Allergy Therapeutics (AIM: AGY), the commercial biotechnology company specialising in allergy immunotherapies, has announced that its VLP Peanut Phase I/IIa PROTECT trial has entered the final phase of treatment. Healthy volunteers are now progressing to the highest dose levels with no safety signals observed, while the third cohort of peanut-allergic patients is also advancing through the dose escalation. The company has also published a new peer-reviewed paper in the Journal of Allergy and Clinical Immunology, validating the mechanism of action of the VLP Peanut vaccine candidate.